Welcome to Neurimmune

Neurimmune is a biopharmaceutical company dedicated to the development of immunotherapeutics for the treatment and prevention of human disorders with a focus on protein aggregation diseases. The current pipeline comprises programs in neurodegeneration including Alzheimer's and Parkinson's diseases, Tauopathies and Amyotrophic Lateral Sclerosis or Lou Gehrig's Disease. Based on its unique RTM™ technology platform (Reverse Translational Medicine), Neurimmune pursues a novel and revolutionary approach for the development of proprietary human monoclonal antibodies as therapeutics with unique advantages that result in superior risk profiles and excellent efficacy.